Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes.

Journal of clinical and experimental hepatology·2026

Same author

A Readability Analysis of Online Patient Education Materials Regarding Endoscopic Retrograde Cholangiopancreatography.

Digestive diseases and sciences·2025

Same author

Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025

Same author

Point-of-Care Testing and Treatment of Hepatitis C Virus in Prisons: The SINTESI Project in Sicily.

Mayo Clinic proceedings. Innovations, quality & outcomes·2025

Same author

An Unexpected Twist: Sigmoid Volvulus Complicated by Peritoneal Metastases.

Cureus·2025

Same author

Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.

Liver international : official journal of the International Association for the Study of the Liver·2025

Search research articles

Related Experiment Video

Updated: May 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

HCV genotype 5: an orphan virus.

Nabil Antaki¹, Dirar Abboud, Fadi Antaki

¹Department of Gastroenterology and Hepatology, Saint Louis Hospital, Aleppo, Syria. nabilantaki@hotmail.com

Antiviral Therapy

|November 1, 2012

Summary

Hepatitis C Virus genotype 5 (HCV-5) is rare, primarily in South Africa. Patients with HCV-5 often present with higher viral loads and more advanced liver fibrosis, complicating treatment decisions.

Area of Science:

Virology
Hepatology
Infectious Diseases

Background:

Hepatitis C Virus genotype 5 (HCV-5) is the least understood genotype, with a limited geographic distribution primarily in South Africa and specific European regions.
Transmission occurs mainly through blood transfusion and iatrogenic means, with sporadic cases globally.
HCV-5 infected patients in endemic areas tend to be older, possess higher viral loads, and exhibit more advanced liver fibrosis compared to those with other genotypes.

Purpose of the Study:

To review the epidemiology, clinical characteristics, and current treatment landscape of Hepatitis C Virus genotype 5.
To highlight the challenges in managing HCV-5 due to limited data and lack of predictive markers for treatment response.

Main Methods:

Literature review of existing studies on HCV-5 epidemiology, transmission, and clinical presentation.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Experiment Videos

Last Updated: May 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Analysis of current treatment guidelines and in vitro data on antiviral activity against HCV-5.

Main Results:

HCV-5 is associated with specific demographic and clinical features, including older age, higher viral load, and advanced fibrosis.
The standard treatment involves 48 weeks of pegylated interferon and ribavirin, with no clear association between IL28B polymorphisms and treatment success.
Predictors for shorter therapy durations are not well-defined, and clinical trials for direct-acting antivirals against HCV-5 are pending.

Conclusions:

HCV-5 presents unique challenges in diagnosis and management due to its distinct clinical profile and limited treatment options.
Further research and clinical trials are crucial to develop more effective and targeted therapies for HCV-5 infections.